Decreased cellular cholesterol efflux is a common cause of familial hypoalphalipoproteinemia: Role of the ABCA1 gene mutations

Atherosclerosis

Volumn 152, Issue 2, 2000, Pages 457-468

  Mott, Stephanie ^a   Yu, Lu ^a   Marcil, Michel ^a   Boucher, Betsie ^a   Rondeau, Colette ^a   Genest, Jacques ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Cholesterol; Familial HDL deficiency; High density lipoproteins (HDL)

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; MALE; PRIORITY JOURNAL; TANGIER DISEASE;

ADULT; ATP-BINDING CASSETTE TRANSPORTERS; CELLS, CULTURED; CHOLESTEROL; CHOLESTEROL, HDL; FEMALE; FIBROBLASTS; HUMANS; HYPOLIPOPROTEINEMIAS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; MUTATION; PEDIGREE; SKIN; TANGIER DISEASE;

EID: 0033816960     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00498-0     Document Type: Article

References (47)

1. Eisenberg S. High density lipoprotein metabolism. J. Lipid Res. 25:1984;1017-1058.
2. Barter P.J., Rye K.-A. High-density lipoproteins and coronary heart disease. Atherosclerosis. 121:1996;1-12.
3. Genest J. Jr, Marcil M., Denis M., Yu L. High density lipoproteins in health and in disease. J. Invest. Med. 47:1999;31-42.
4. Castelli W.P., Garrison R.J., Wilson P.W., Abbott R.D., Kalousdian S., Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. J. Am. Med. Acad. 256:1986;2835-2838.
5. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am. J. Med. 62:1977;707-714.
6. Genest J. Jr, McNamara J.R., Ordovas J.M., et al. Lipoprotein cholesterol apolipoprotein A-1 and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J. Am. Coll. Cardiol. 1979:1992;27-28.
7. Assmann G., Schulte H., von Eckardstein A., Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 124:1996;1-20.
8. Goldbourt U., Medalie J.H. High-density lipoprotein cholesterol and incidence of coronary heart disease-the Israeli Ischemic heart disease study. Am. J. Epidemiol. 109:1979;296-308.
9. Milano, associated with hypoalphalipoproteinemia. J. Clin. Invest. 91:1993;1445-1452.
10. Calabresi L., Franceschini G. High density lipoprotein and coronary heart disease: insights from mutations leading to low high density lipoprotein. Curr. Opin. Lipidol. 8:1997;219-224.
11. Genest J. Jr, Cohn J. Plasma triglyceride-rich lipoproteins and high density lipoprotein disorders associated with atherosclerosis: biomedicine’98 vascular biology symposium. J. Invest. Med. 46:1998;351-358.
12. Gaziano J.M., Hennekens C.H., O’Donnell C.J., Breslow J.L. Fasting triglycerides, high density lipoprotein, and risk of myocardial infarction. Circulation. 96:1997;2520-2525.
13. Genest J. Jr, Bard J.-M., Fruchart J.-C., Ordovas J.M., Schaefer E.J. Familial hypoalphalipoproteinemia in premature coronary artery disease. Arterioscler. Thromb. 13:1993;1728-1737.
14. Assmann G., vonEckardstein A., Brewer H.B. Familial high density lipoprotein deficiency: Tangier disease. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The metabolic and molecular basis of inherited disease. 7th:1995;2053-2072 McGraw-Hill, USA.
15. Marcil M., Boucher B., Frohlich J., Davignon J., Solymoss B.C., Genest J. Jr. Severe familial HDL deficiency (FHD) in French Canadian kindred: clinical, biochemical and molecular characterization. Arterioscler. Thromb. Vasc. Biol. 15:1995;1015-1024.
16. Schaefer E.J., Ordovas J.M. Metabolism of apolipoproteins A-1, A-II, and A-IV. Meth. Enzymol. 129:1986;420-443.
17. Batal R., Tremblay M., Krimbou L., Mamer O., Davignon J., Genest J. Jr, Cohn J.S. Familial deficiency characterized by hypercatabolism of mature apoA-1 but not proapoAI. Atheroscler. Thromb. Vasc. Biol. 18:1998;655-664.
18. Walter M., Gerdes U., Seedorf U., Assmann G. The high density lipoprotein- and apolipoprotein AI-induced mobilization of cellular cholesterol is impaired in fibroblasts from Tangier disease subjects. Biochem. Biopyhs. Res. Commun. 205:1994;850-856.
19. Francis G.A., Knopp R.H., Oram J.F. Defective removal of cellular cholesterol and phospholipids by apolipoprotein Al in Tangier disease. J. Clin. Invest. 96:1995;78-87.
20. Rogler G., Trumbach B., Klima B., Lackner K.J., Schmitz G. HDL-mediated efflux of intracellular cholesterol is impared in fibroblasts from Tangier disease patients. Arterioscler. Thromb. Vasc. Biol. 15:1995;683-690.
21. Remaley A.T., Schumacher J.A., Farsi J.A., Nazih B.D., Brewer H.B. Jr. Decreased reverse cholesterol transport from Tangier disease fibroblasts: acceptor specificity and effects of brefeldin on lipid efflux. Atheroscler. Thromb. Vasc. Biol. 17:1997;1813-1821.
22. Brooks-Wilson A., Marcil M., Clee S., et al. Mutations in the ATP binding cassette (ABC1) transporter genein Tangier disease and familial HDL deficiency (FHA). Nat. Genet. 22:1999;336-345.
23. Bodzioch M., Orso E., Klucken J., et al. Nat. Genet. 22:1999;347-351.
24. Rust S., Rosier M., Funke H., et al. Tangier disease is caused by mutations in the gene encoding ATP binding cassette transporter 1. Nat. Genet. 22:1999;352-355.
25. Marcil M., Brooks-Wilson A., Clee S., et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet. 354:1999;1341-1346.
26. Genest J. Jr, Martin-Munley S.S., McNamara J.R., et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 85:1992;2025-2033.
27. Weber M., McNicoll S., Marcil M., et al. Metabolic factors clustering lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery desease in French Canadians. Can. J. Cardiol. 13:1997;253-260.
28. Marcil M., Lu Y., Krimbou L., Boucher B., Oram J., Cohn J.S., Genest J. Jr. Cellular cholesterol transport and efflux from fibroblasts are abnormal in subjects with familial HDL deficiency. Arterioscler. Thromb. Vasc. Biol. 19:1999;159-169.
29. The Lipid Research Clinics Population Studies Data Book, vol. 1. The prevalence study. Washington, D.C.: Department of Health and Human Services, Public Health Service, July 1980 p.28-81. (NIH publication number 80-1527).
30. Serfaty-Lacrosniere C., Civeira F., Lanzberg A., et al. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis. 107:1994;85-98.
31. Genest J. Jr, McNamara J.R., Salem D.N., Schaefer E.L. Prevalence of risk factors in men with premature coronary artery disease. Am. J. Cardiol. 67:1991;1185-1189.
32. Emmerich J., Verges B., Tauveron I., et al. Familial HDL deficiency due to marked hypercatabolism of normalapoA-I. Arterioscler. Thromb. 13:1993;1299-1306.
33. Eberhart G.P., Mendez A.J., Freeman M.W. Decreased cholesterol efflux from fibroblasts of a patient without Tangier disease, but with markedly reduced high density lipoprotein cholesterol levels. J. Clin. Endocrinol. Metab. 83:1998;836-846.
34. Fielding G., Fielding P.E. Intracellular cholesterol transport. J. Lipid Res. 38:1997;1503-1521.
35. Liscum L., Munn N.J. Intracellular cholesterol transport. Biochern. Biophys. Acta. 1438:1999;19-37.
36. Phillips M.C., Gillotte K.L., Haynes M.P., Johnson W.J., Lund-Katz S., Rothblat G.H. Mechanisms of high density lipoprotein-mediated efflux of cholesterol from cell plasma membranes. Atherosclerosis. 137:1998;13-17.
37. De la Llera Moya M., Atger V., Paul J.L., et al. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux: relations between serum components and efflux, esterification, and transfer. Arterio. Thromb. 14:1994;1056-1065.
38. Davidson W.S., Gillotte K.L., Lund-Katz S., et al. J. Biol. Chem. 270:1995;5882-5890.
39. Fidge N. High density lipoprotein receptors, binding proteins, and ligands. J. Lipid Res. 40:1999;187-201.
40. Mendez A.J., Oram J.F., Bierman E.L. Protein kinase C as a mediator of high density lipoprotein receptor-dependent efflux of intracellular cholesterol. J. Biol. Chem. 266:1991;10104-10111.
41. Choi S.W., Park H.Y., Rubeiz N.G., Sachs D., Gilchrest B.A. Protein kinase C-alpha levels are inversely associated with growth rate in cultured human dermal fibroblasts. J. Dermatol. Sci. 18:1998;54-63.
42. Deeg M.A., Garver W.S., Bierman E.L., Oram J.F. HDL stimulates phosphorylation of 18 and 80 kDa proteins in cholesterol-loaded human skin fibroblasts. Circulation. 88:1993;1215. Abstracts.
43. Deeg M.A., Bowen R.F., Oram J.F., Bierman E.L. High density lipoproteins stimulate mitogen activated protein kinases in human skin fibroblasts. Arterioscler. Thromb. Vasc. Biol. 17:1997;1667-1674.
44. Walter M., Reinecke H., Gerdes U., et al. Defective regulation of phosphatidylcholine-specific phospholipases C and D in a kindred with Tangier disease: evidence for the involvement of phosphatidylcholine breakdown in HDL- mediatedcholesterol efflux mechanisms. J. Clin. Invest. 98:1996;2315-2323.
45. Liscum L., Underwood K.W. Intracellular cholesterol transport and compartmentation. J. Biol. Chem. 270:1995;15443-15446.
46. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 343:1990;425-430.
47. Mendez A.J., Uint L. Apolipoprotein-mediated cellular cholesterol and phospholipid efflux depend on a functional Golgi apparatus. J. Lipid Res. 37:1996;2510-2524.